Overview

Useful For
Determining whether absence of MSH6 protein, by immunohistochemistry in tumor tissue, is associated with a germline mutation in the affected individual

Establishing a diagnosis of Lynch syndrome/hereditary nonpolyposis colorectal cancer

Genetics Test Information
Prior Authorization is available for this assay; see Special Instructions.

Additional Tests

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Reporting Name</th>
<th>Available Separately</th>
<th>Always Performed</th>
</tr>
</thead>
<tbody>
<tr>
<td>COLAB</td>
<td>Hereditary Colon Cancer CGH Array</td>
<td>Yes, (Order FMTT)</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Testing Algorithm
When this test is ordered, comparative genomic hybridization array will always be performed at an additional charge.

See Lynch Syndrome Testing Algorithm in Special Instructions.

Special Instructions
- Molecular Genetics: Inherited Cancer Syndromes Patient Information
- Informed Consent for Genetic Testing
- Lynch Syndrome (MSH6) Full Gene Analysis Prior Authorization Ordering Instructions
- Lynch Syndrome Testing Algorithm
- Informed Consent for Genetic Testing (Spanish)

Method Name
Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing

NY State Available
Yes

Specimen

Specimen Type
Varies

Shipping Instructions
Specimen preferred to arrive within 96 hours of draw.

Specimen Required
Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.
Specimen Type: Whole blood

Container/Tube:

Preferred: Lavender top (EDTA) or yellow top (ACD)
Acceptable: Any anticoagulant

Specimen Volume: 3 mL

Collection Instructions:
1. Invert several times to mix blood.
2. Send specimen in original tube.

Additional Information: Prior Authorization is available for this test. Submit the required form with the specimen.

Forms
1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available in Special Instructions:
   - Informed Consent for Genetic Testing (T576)
   - Informed Consent for Genetic Testing-Spanish (T826)
2. Molecular Genetics: Inherited Cancer Syndromes Patient Information (T519) in Special Instructions
3. Lynch Syndrome (MSH6) Full Gene Analysis Prior Authorization Ordering Instructions in Special Instructions
4. If not ordering electronically, complete, print, and send a Oncology Test Request (T729) with the specimen.

Specimen Minimum Volume
1 mL

Reject Due To
No specimen should be rejected.

Specimen Stability Information

<table>
<thead>
<tr>
<th>Specimen Type</th>
<th>Temperature</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Varies</td>
<td>Ambient (preferred)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Frozen</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Refrigerated</td>
<td></td>
</tr>
</tbody>
</table>

Clinical and Interpretive

Clinical Information
Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer or HNPCC) is an autosomal dominant hereditary cancer syndrome associated with germline mutations in the mismatch repair genes, MLH1, MSH2, MSH6, and PMS2. Deletions within the 3-prime end of the EPCAM gene have also been associated with Lynch syndrome, as this leads to inactivation of the MSH2 promoter.

Lynch syndrome is predominantly characterized by significantly increased risks for colorectal and endometrial cancer. The lifetime risk for colorectal cancer is highly variable and dependent on the gene involved. The risk for colorectal cancer-associated MLH1 and MSH2 mutations (approximately 50%-80%) is generally higher than the risks associated with mutations in the other Lynch syndrome-related genes. The lifetime risk for endometrial cancer (approximately 25%-60%) is also highly variable. Other malignancies within the tumor spectrum include gastric cancer, ovarian cancer, hepatobiliary and urinary tract carcinomas, and small bowel cancer. The lifetime risks for these cancers are <15%. Of the 4 mismatch repair genes, mutations within the PMS2 gene confer the lowest risk for any of the tumors within the Lynch syndrome spectrum.

Several clinical variants of Lynch syndrome have been defined. These include Turcot syndrome, Muir-Torre syndrome, and homozygous mismatch repair mutations (also called constitutional mismatch repair deficiency syndrome). Turcot syndrome and Muir-Torre syndrome are associated with increased risks for cancers within the tumor spectrum described but also include brain/central nervous system malignancies and sebaceous carcinomas, respectively. Homozygous mismatch repair mutations, characterized by the presence of biallelic deleterious mutations within a mismatch repair gene, are associated with a different clinical phenotype defined by hematologic and brain cancers, cafe au lait macules, and childhood colon or small bowel cancer.

There are several strategies for evaluating individuals whose personal or family history of cancer is suggestive of Lynch syndrome. One such strategy involves testing the tumors from suspected individuals for microsatellite instability (MSI) and immunohistochemistry (IHC) for the presence or absence of defective DNA mismatch repair. Tumors that demonstrate absence of expression of MSH6 are more likely to have a germline mutation in the MSH6 gene.

Reference Values
An interpretive report will be provided.

Interpretation
All detected alterations will be evaluated according to American College of Medical Genetics and Genomics (ACMG) recommendations.(1) Variants will be classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.

Cautions
Some individuals who have a diagnosis of MSH6-related Lynch syndrome may have a mutation that is not identified by this method (e.g., promoter mutations, deep intronic mutations). The absence of a mutation, therefore, does not eliminate the possibility of a diagnosis of Lynch syndrome. For predictive testing, it is important to first document the presence of an MSH6 gene mutation in an affected family member.

In some cases, DNA alterations of undetermined significance may be identified.

Rare polymorphisms exist that could lead to false-negative or false-positive results. If results obtained do not match the clinical findings, additional testing should be considered.

Test results should be interpreted in the context of clinical findings, family history, and other laboratory data. Errors in our interpretation of results may occur if information given is inaccurate or incomplete.

We strongly recommend that patients undergoing predictive testing receive genetic counseling both prior to testing and after results are available.
Supportive Data
Specimens from approximately 37 patients were tested by DNA sequence analysis and the results compared to those obtained by sequence analysis from other laboratories. All results were 100% concordant.

Clinical Reference


Performance

Method Description
Bidirectional sequence analysis is performed to test for the presence of a mutation in all coding regions and intron/exon boundaries of the MSH6 gene. Additionally, array comparative genomic hybridization (aCGH) is used to test for the presence of large deletions and duplications in this gene.(Aradhya S, Lewis R, Bonaga T, et al: Exon-level array CGH in a large clinical cohort demonstrates increased sensitivity of diagnostic testing for Mendelian disorders. Genet Med 2012;14[6]:594-603)

PDF Report
No

Day(s) and Time(s) Test Performed
Performed weekly; Varies

Analytic Time
14 days

Maximum Laboratory Time
20 days

Performing Laboratory Location
Rochester

Fees and Codes

Fees
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
Test Definition: MSH6Z
MSH6 Gene, Full Gene Analysis

- Prospective clients should contact their Regional Manager. For assistance, contact Customer Service.

Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information
81298-MSH6 (mutS homolog 6[E.coli]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis

81228-Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number variants (eg, bacterial artificial chromosome [BAC] or oligo-based comparative genomic hybridization [CGH] microarray analysis)

LOINC® Information

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Test Order Name</th>
<th>Order LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSH6Z</td>
<td>MSH6 Gene, Full Gene Analysis</td>
<td>In Process</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Result ID</th>
<th>Test Result Name</th>
<th>Result LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>53592</td>
<td>Result Summary</td>
<td>50397-9</td>
</tr>
<tr>
<td>53593</td>
<td>Result</td>
<td>82939-0</td>
</tr>
<tr>
<td>53594</td>
<td>Interpretation</td>
<td>69047-9</td>
</tr>
<tr>
<td>53595</td>
<td>Additional Information</td>
<td>48767-8</td>
</tr>
<tr>
<td>53596</td>
<td>Specimen</td>
<td>31208-2</td>
</tr>
<tr>
<td>53597</td>
<td>Source</td>
<td>31208-2</td>
</tr>
<tr>
<td>53598</td>
<td>Array Billed?</td>
<td>No LOINC Needed</td>
</tr>
<tr>
<td>53599</td>
<td>Released By</td>
<td>18771-6</td>
</tr>
</tbody>
</table>

Prior Authorization
Insurance preauthorization is available for this testing; forms are available in Special Instructions.

Patient financial assistance may be available to those who qualify. Patients who receive a bill from Mayo Clinic Laboratories will receive information on eligibility and how to apply.